Market growth factors such as the rising incidence of target infectious diseases and genetic disorders; technological advancements in PCR technologies; increasing investments, funds, and grants; increasing use of biomarker profiling for disease diagnostics; and successful completion of the Human Genome Project are driving the growth of the Digital PCR Market.
According to research report the global Digital PCR Market size is highly competitive. The market is estimated to grow to USD 7.6 billion by 2025 from USD 4.9 billion in 2020, at a CAGR of 9.0%.
Download PDF Brochure: https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=174151204
By identifying over 30,000+ growth opportunities through our unique market research methodology, markets and market help grow your business, drive market performance and assess potential business disruptors.
The market is segmented by Product (Instruments, Reagents Consumables, Software Services), Application (Clinical, Research, Forensic), End User (Hospitals Diagnostic Centers, Pharma Biotech, CROs) and Region.
- Based on products services, the Digital PCR Product Market is categorized into reagents and consumables, instruments and software services. The qPCR reagents and consumables segment is expected to command the largest share of the qPCR products services market in 2020, owing to the factors such as the expanding applications of qPCR, growing private-public funding for life science research, and the rising number of probe-based multiplex genetic analysis procedures (that require the analysis of low-volume gene samples).
- Based on application, the Digital PCR Market is categorized into clinical applications (Infectious Disease Testing, Oncology Testing, Blood Screening, Transplant Diagnostics and Other Clinical Applications), research applications and forensic applications.The key factors driving the market growth of cclinical applications segment include the growing usage of qPCR in disease diagnosis, rising incidence of infectious and genetic diseases, and growing public emphasis on early effective disease diagnosis treatment. The clinical applications segment is estimated to dominate the qPCR applications market in 2020.
- Based on end users, the qPCR market is segmented into research laboratories and academic institutes, pharmaceutical and biotechnology companies, hospitals and diagnostic centers, clinical research organizations (CROs), and forensic laboratories. This can be attributed to the increasing market availability of qPCR reagents for clinical diagnostic applications, ongoing expansion of healthcare infrastructure across emerging countries, high prevalence of target diseases, and growing awareness among end users related to the benefits offered by qPCR for clinical diagnosis. In 2019, the hospitals and diagnostic centers segment accounted for the largest share of the market.
- North America accounted for the largest share of the dPCR and qPCR market, followed by Europe in 2019. The large share of the North American regional segment can be attributed to the increased adoption of innovative and novel genomic analysis products, expanding use of PCR techniques in clinical diagnostics forensics, and early commercialization of qPCR/dPCR products compared to other regions.
The global dPCR and qPCR market is highly competitive, with many large, medium-sized, and small market players. As of the financial year ended in March 2019, the global dPCR and qPCR market was dominated by Thermo Fisher Scientific (US), Bio-Rad Laboratories Inc. (US), and F. Hoffmann-La Roche, Ltd. (Switzerland).
Request For Sample Pages: https://www.marketsandmarkets.com/requestsampleNew.asp?id=174151204
Thermo Fisher Scientific held the leading position in the Digital PCR Market in 2019. Thermo Fisher Scientific focuses on strengthening its position in the market by adopting organic and inorganic strategies such as product launches and expansions. In line with this strategy, Thermo Fisher Scientific launched several products, including the SureTect Cronobacter Species Real-Time PCR Assay (2016), Axiom Africa Array (2017), QuantStudio 5 Real-Time PCR System (2017), and TaqMan Digital PCR Liquid Biopsy Assays (2017). To combat the COVID-19 outbreak, Thermo Fisher Scientific also developed several PCR kits and assays for diagnostics and research. It received US FDA EUA for the SARS‑CoV‑2 multiplex real-time PCR test and launched the AcroMetrix Coronavirus 2019 (COVID-19) RNA Control in 2020.
Mr. Aashish Mehra
630 Dundee Road
Northbrook, IL 60062
USA : 1-888-600-6441